Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2021 | Breast Cancer | Research

In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers

Author: Jongchan Kim

Published in: World Journal of Surgical Oncology | Issue 1/2021

Abstract

Background

Identification of specific biological functions, pathways, and appropriate prognostic biomarkers is essential to accurately predict the clinical outcomes of and apply efficient treatment for breast cancer patients.

Methods

To search for metastatic breast cancer-specific biological functions, pathways, and novel biomarkers in breast cancer, gene expression datasets of metastatic breast cancer were obtained from Oncomine, an online data mining platform. Over- and under-expressed genesets were collected and the differentially expressed genes were screened from four datasets with large sample sizes (N > 200). They were analyzed for gene ontology (GO), KEGG pathway, protein-protein interaction, and hub gene analyses using online bioinformatic tools (Enrichr, STRING, and Cytoscape) to find enriched functions and pathways in metastatic breast cancer. To identify novel prognostic biomarkers in breast cancer, differentially expressed genes were screened from the entire twelve datasets with any sample sizes and tested for expression correlation and survival analyses using online tools such as KM plotter and bc-GenExMiner.

Results

Compared to non-metastatic breast cancer, 193 and 144 genes were differentially over- and under-expressed in metastatic breast cancer, respectively, and they were significantly enriched in regulating cell death, epidermal growth factor receptor signaling, and membrane and cytoskeletal structures according to the GO analyses. In addition, genes involved in progesterone- and estrogen-related signalings were enriched according to KEGG pathway analyses. Hub genes were identified via protein-protein interaction network analysis. Moreover, four differentially over-expressed (CCNA2, CENPN, DEPDC1, and TTK) and three differentially under-expressed genes (ABAT, LRIG1, and PGR) were further identified as novel biomarker candidate genes from the entire twelve datasets. Over- and under-expressed biomarker candidate genes were positively and negatively correlated with the aggressive and metastatic nature of breast cancer and were associated with poor and good prognosis of breast cancer patients, respectively.

Conclusions

Transcriptome datasets of metastatic breast cancer obtained from Oncomine allow the identification of metastatic breast cancer-specific biological functions, pathways, and novel biomarkers to predict clinical outcomes of breast cancer patients. Further functional studies are needed to warrant validation of their roles as functional tumor-promoting or tumor-suppressing genes.

Available only for authorised users

De Vita VT Jr. Breast cancer therapy: exercising all our options. N Engl J Med. 1989;320(8):527–9. https://doi.org/10.1056/NEJM198902233200812.CrossRefPubMed

Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24(3):511–20. https://doi.org/10.1158/1078-0432.CCR-16-3001.CrossRefPubMed

Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11(2):101–15. https://doi.org/10.7497/j.issn.2095-3941.2014.02.005.CrossRefPubMedPubMedCentral

Kulkarni A, Stroup AM, Paddock LE, Hill SM, Plascak JJ, Llanos AAM. Breast cancer incidence and mortality by molecular subtype: statewide age and racial/ethnic disparities in New Jersey. Cancer Health Disparities. 2019;3:e1–e17. https://doi.org/10.9777/chd.2019.1012.CrossRefPubMedPubMedCentral

Howlader N, Noone AM, Krapcho M, (editors). ea. Table 4.5: Cancer of the breast (invasive). Age-adjusted SEER incidence rates by year, race and sex. National Cancer Institute. Bethesda, MD. Accessed on April 27, 2020. https://seer.cancer.gov/csr/1975_2017/. Cancer Statistics Review, 1975-2017. 2020.

Howlader N NA, Krapcho M, et al. (editors). Cancer Statistics Review, 1975-2017. Table 4.13: Cancer of the female breast (invasive): 5-year relative and period survival by race, diagnosis year, age and stage at diagnosis. National Cancer Institute. Bethesda, MD. Accessed on April 27, 2020. https://seer.cancer.gov/csr/1975_2017/, 2020.

Ghafouri-Fard S, Oskooei VK, Azari I, Taheri M. Suppressor of cytokine signaling (SOCS) genes are downregulated in breast cancer. World J Surg Oncol. 2018;16(1):226. https://doi.org/10.1186/s12957-018-1529-9.CrossRefPubMedPubMedCentral

Jia R, Li Z, Liang W, Ji Y, Weng Y, Liang Y, et al. Identification of key genes unique to the luminal a and basal-like breast cancer subtypes via bioinformatic analysis. World J Surg Oncol. 2020;18(1):268. https://doi.org/10.1186/s12957-020-02042-z.CrossRefPubMedPubMedCentral

Liu X, Jin G, Qian J, Yang H, Tang H, Meng X, et al. Digital gene expression profiling analysis and its application in the identification of genes associated with improved response to neoadjuvant chemotherapy in breast cancer. World J Surg Oncol. 2018;16(1):82. https://doi.org/10.1186/s12957-018-1380-z.CrossRefPubMedPubMedCentral

10.

Mao XH, Ye Q, Zhang GB, Jiang JY, Zhao HY, Shao YF, et al. Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer. World J Surg Oncol. 2021;19(1):29. https://doi.org/10.1186/s12957-021-02124-6.CrossRefPubMedPubMedCentral

11.

Mohamadalizadeh-Hanjani Z, Shahbazi S, Geranpayeh L. Investigation of the SPAG5 gene expression and amplification related to the NuMA mRNA levels in breast ductal carcinoma. World J Surg Oncol. 2020;18(1):225. https://doi.org/10.1186/s12957-020-02001-8.CrossRefPubMedPubMedCentral

12.

Yuan Q, Zheng L, Liao Y, Wu G. Overexpression of CCNE1 confers a poorer prognosis in triple-negative breast cancer identified by bioinformatic analysis. World J Surg Oncol. 2021;19(1):86. https://doi.org/10.1186/s12957-021-02200-x.CrossRefPubMedPubMedCentral

13.

Zhou X, Xiao C, Han T, Qiu S, Wang M, Chu J, et al. Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis. World J Surg Oncol. 2020;18(1):254. https://doi.org/10.1186/s12957-020-02026-z.CrossRefPubMedPubMedCentral

14.

Zhu C, Hu H, Li J, Wang J, Wang K, Sun J. Identification of key differentially expressed genes and gene mutations in breast ductal carcinoma in situ using RNA-seq analysis. World J Surg Oncol. 2020;18(1):52. https://doi.org/10.1186/s12957-020-01820-z.CrossRefPubMedPubMedCentral

15.

Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6. https://doi.org/10.1016/S1476-5586(04)80047-2.CrossRefPubMedPubMedCentral

16.

Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.CrossRef

17.

Dai X, Cheng H, Bai Z, Li J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J Cancer. 2017;8(16):3131–41. https://doi.org/10.7150/jca.18457.CrossRefPubMedPubMedCentral

18.

Jiang G, Zhang S, Yazdanparast A, Li M, Pawar AV, Liu Y, et al. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics. 2016;17 Suppl 7:525.

19.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515–27. https://doi.org/10.1016/j.ccr.2006.10.008.CrossRefPubMedPubMedCentral

20.

Ghadie M, Xia Y. Estimating dispensable content in the human interactome. Nat Commun. 2019;10(1):3205. https://doi.org/10.1038/s41467-019-11180-2.CrossRefPubMedPubMedCentral

21.

Wodak SJ, Pu S, Vlasblom J, Seraphin B. Challenges and rewards of interaction proteomics. Mol Cell Proteomics. 2009;8(1):3–18. https://doi.org/10.1074/mcp.R800014-MCP200.CrossRefPubMed

22.

Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, et al. Triple negative breast cancer - an overview. Hereditary Genet. 2013;2013(Suppl 2).

23.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368–76. https://doi.org/10.1158/1078-0432.CCR-07-1658.CrossRefPubMed

24.

Oner G, Altintas S, Canturk Z, Tjalma W, Verhoeven Y, Van Berckelaer C, et al. Triple-negative breast cancer-role of immunology: a systemic review. Breast J. 2019.

25.

Toft DJ, Cryns VL. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol. 2011;25(2):199–211. https://doi.org/10.1210/me.2010-0164.CrossRefPubMed

26.

Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98. https://doi.org/10.1158/2159-8290.CD-18-1177.CrossRefPubMedPubMedCentral

27.

Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. https://doi.org/10.1186/s13058-020-01296-5.CrossRefPubMedPubMedCentral

28.

Hortobagyi GN, Connolly JL, D’Orsi CJ, Edge SB, Mittendorf EA, Rugo HS, et al. Breast. Eighth Edition: AJCC Cancer Staging Manual; 2017.

29.

Li JQ, Miki H, Wu F, Saoo K, Nishioka M, Ohmori M, et al. Cyclin A correlates with carcinogenesis and metastasis, and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms. Hum Pathol. 2002;33(10):1006–15. https://doi.org/10.1053/hupa.2002.125774.CrossRefPubMed

30.

Yang L, Zeng W, Sun H, Huang F, Yang C, Cai X, et al. Bioinformatical analysis of Gene Expression Omnibus database associates TAF7/CCNB1, TAF7/CCNA2, and GTF2E2/CDC20 pathways with glioblastoma development and prognosis. World Neurosurg. 2020;138:e492–514. https://doi.org/10.1016/j.wneu.2020.02.159.CrossRefPubMed

31.

Yasmeen A, Berdel WE, Serve H, Muller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2003;3(5):617–33. https://doi.org/10.1586/14737159.3.5.617.CrossRefPubMed

32.

Mellone B, Erhardt S, Karpen GH. The ABCs of centromeres. Nat Cell Biol. 2006;8(5):427–9. https://doi.org/10.1038/ncb0506-427.CrossRefPubMed

33.

Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T, et al. Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res. 2010;70(14):5829–39. https://doi.org/10.1158/0008-5472.CAN-10-0255.CrossRefPubMed

34.

Lauze E, Stoelcker B, Luca FC, Weiss E, Schutz AR, Winey M. Yeast spindle pole body duplication gene MPS1 encodes an essential dual specificity protein kinase. EMBO J. 1995;14(8):1655–63.CrossRef

35.

Mason JM, Wei X, Fletcher GC, Kiarash R, Brokx R, Hodgson R, et al. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017;114(12):3127–32. https://doi.org/10.1073/pnas.1700234114.CrossRefPubMedPubMedCentral

36.

Chandler BC, Moubadder L, Ritter CL, Liu M, Cameron M, Wilder-Romans K, et al. TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. J Clin Invest. 2020;130(2):958–73. https://doi.org/10.1172/JCI130435.CrossRefPubMedPubMedCentral

37.

Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, et al. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Mol Oncol. 2015;9(6):1218–33. https://doi.org/10.1016/j.molonc.2015.02.006.CrossRefPubMedPubMedCentral

38.

Chen X, Cao Q, Liao R, Wu X, Xun S, Huang J, et al. Loss of ABAT-mediated GABAergic system promotes basal-like breast cancer progression by activating Ca(2+)-NFAT1 axis. Theranostics. 2019;9(1):34–47. https://doi.org/10.7150/thno.29407.CrossRefPubMedPubMedCentral

39.

Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004;23(16):3270–81. https://doi.org/10.1038/sj.emboj.7600342.CrossRefPubMedPubMedCentral

40.

Ji Y, Kumar R, Gokhale A, Chao HP, Rycaj K, Chen X, et al. LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor. Semin Cancer Biol. 2021. https://doi.org/10.1016/j.semcancer.2020.12.016.

41.

Li Q, Liu B, Chao HP, Ji Y, Lu Y, Mehmood R, et al. LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer. Nat Commun. 2019;10(1):5494. https://doi.org/10.1038/s41467-019-13532-4.CrossRefPubMedPubMedCentral

42.

Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, et al. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Oncogene. 2016;35(9):1206. https://doi.org/10.1038/onc.2015.418.CrossRefPubMed

43.

Torigoe H, Yamamoto H, Sakaguchi M, Youyi C, Namba K, Sato H, et al. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR. Carcinogenesis. 2018;39(5):719–27. https://doi.org/10.1093/carcin/bgy044.CrossRefPubMed

44.

Braun L, Mietzsch F, Seibold P, Schneeweiss A, Schirmacher P, Chang-Claude J, et al. Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss. Mod Pathol. 2013;26(9):1161–71. https://doi.org/10.1038/modpathol.2013.60.CrossRefPubMed

45.

Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014;110(3):565–72. https://doi.org/10.1038/bjc.2013.756.CrossRefPubMed

46.

Ueno T, Saji S, Chiba T, Kamma H, Isaka H, Itoh H, et al. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer. Tumour Biol. 2018;40(10):1010428318811025. https://doi.org/10.1177/1010428318811025.CrossRefPubMed

47.

Van Belle V, Van Calster B, Brouckaert O, Vanden Bempt I, Pintens S, Harvey V, et al. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. J Clin Oncol. 2010;28(27):4129–34. https://doi.org/10.1200/JCO.2009.26.4200.CrossRefPubMed

48.

Moore AT, Rankin KE, von Dassow G, Peris L, Wagenbach M, Ovechkina Y, et al. MCAK associates with the tips of polymerizing microtubules. J Cell Biol. 2005;169(3):391–7. https://doi.org/10.1083/jcb.200411089.CrossRefPubMedPubMedCentral

49.

Shao H, Huang Y, Zhang L, Yuan K, Chu Y, Dou Z, et al. Spatiotemporal dynamics of Aurora B-PLK1-MCAK signaling axis orchestrates kinetochore bi-orientation and faithful chromosome segregation. Sci Rep. 2015;5(1):12204. https://doi.org/10.1038/srep12204.CrossRefPubMedPubMedCentral

50.

Li TF, Zeng HJ, Shan Z, Ye RY, Cheang TY, Zhang YJ, et al. Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer. Cancer Cell Int. 2020;20(1):123. https://doi.org/10.1186/s12935-020-01191-1.CrossRefPubMedPubMedCentral

51.

Shimo A, Tanikawa C, Nishidate T, Lin ML, Matsuda K, Park JH, et al. Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci. 2008;99(1):62–70. https://doi.org/10.1111/j.1349-7006.2007.00635.x.CrossRefPubMed

52.

Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer. 2008;122(5):1089–94. https://doi.org/10.1002/ijc.22892.CrossRefPubMed

53.

Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988;6(7):1076–87. https://doi.org/10.1200/JCO.1988.6.7.1076.CrossRefPubMed

54.

Hua H, Zhang H, Kong Q, Jiang Y. Mechanisms for estrogen receptor expression in human cancer. Exp Hematol Oncol. 2018;7(1):24. https://doi.org/10.1186/s40164-018-0116-7.CrossRefPubMedPubMedCentral

55.

Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia GD, Lauro VD, et al. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. Int J Mol Sci. 2020;21(18).

56.

Ali R, Wendt MK. The paradoxical functions of EGFR during breast cancer progression. Signal Transduct Target Ther. 2017;2(1). https://doi.org/10.1038/sigtrans.2016.42.

57.

Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150(1):165–78. https://doi.org/10.1016/j.cell.2012.04.042.CrossRefPubMedPubMedCentral

58.

Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. https://doi.org/10.1038/nature11412.CrossRef

Title: In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers
Author: Jongchan Kim
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Biomarkers
Published in: World Journal of Surgical Oncology / Issue 1/2021
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-021-02301-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Laennec’s approach for laparoscopic anatomical hemihepatectomy

T stage and venous invasion are crucial prognostic factors for long-term survival of patients with remnant gastric cancer: a cohort study

Prognostic factors for ovarian metastases in colorectal cancer patients

Impact of skeletal muscle mass in patients with recurrent gastric cancer

Retraction Note: Urachal tumour: case report of a poorly understood carcinoma

Microarray profile analysis identifies ETS1 as potential biomarker regulated by miR-23b and modulates TCF4 in gastric cancer